SubHero Banner
Text

4th Quarter 2017

Key topics in this quarter’s edition include:

  • Ibalizumab: treatment of adults with HIV-1 infection resistant to ≥ 1 agent in three different drug classes
  • Ivacaftor/tezacaftor: treatment of cystic fibrosis patients ≥ 12 years of age who have at least one copy of the F508del mutation

Download PDF

Text